<DOC>
	<DOCNO>NCT00678574</DOCNO>
	<brief_summary>The purpose study propose investigate role neurosteroids GABA pathophysiology treatment premenstrual dysphoric disorder ( PMDD ) 1 ) measure cortical gama-aminobutyric acid level ( GABA level ) use nuclear magnetic resonance spectroscopy ( MRS ) follicular mid-luteal phase menstrual cycle pre post treatment selective serotonin reuptake inhibitor ( SSRI ) fluoxetine ( Prozac® , Sarafem® ) , 2 ) correlate cerebrospinal fluid ( CSF ) plasma GABA neurosteroid level cortical GABA level time point . Neurosteroids measure include allopregnanolone , pregnenolone , pregnenolone sulfate . Findings woman PMDD compare healthy subject .</brief_summary>
	<brief_title>The Role GABA Neurosteroids Premenstrual Dysphoric Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Premenstrual Syndrome</mesh_term>
	<mesh_term>Premenstrual Dysphoric Disorder</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Neurotransmitter Agents</mesh_term>
	<criteria>Aged 18 45 year old able give voluntary write informed consent . Willing complete daily log mood symptom 7 consecutive menstrual cycle : two menstrual cycle Screening Phase ( Phase 1 ) , one menstrual cycle Testing Phase ( Phase 2 ) , four menstrual cycle Medication Treatment Phase PostTreatment Phase ( Phase 3 ) . All subject successfully complete Phases 1 2 , Medication Treatment Phase , invite participate Phase 3 approximately three month later . Phase 3 involve repeat procedure conduct Phase 2 , include daily log mood symptom . Meet DSMIV criterion premenstrual dysphoric disorder , confirm Daily Record Severity Problems ( DRSP ; Endicott &amp; Harrison ) 2 consecutive menstrual cycle ( Phase 1 ) . The DRSP selfrated symptom checklist , require individual rate symptom PMDD accord DSMIV research criterion scale scale 1 ( symptom present ) 6 ( symptom extreme ) . During last 7 day menstrual cycle compare day 511 , patient must 30 % increase average ( 2 menstrual cycle ) score 5 10 symptom . Symptoms must `` present '' `` minimal '' postmenstrual week . Average 19item Hamilton Depression Rating Scale ( HAMD ) score &lt; 5 follicular phase &gt; 16 luteal phase . Have regular menstrual cycle 28 32 day length . Each screen cycle must ovulatory confirmed plasma progesterone level &gt; 5 ng/ml luteal phase . Presence comorbid DSMIV Axis I disorder . Meeting DSMIV criterion psychoactive substance ( exclude nicotine ) dependence within precede 4 month . A history serious medical neurological illness , include ( limit ) major cardiovascular disease , severe hypertension , intracranial mass lesion , seizure disorder , severe hepatic renal disease , unstable endocrine metabolic disease , unstable hematologic disease . Use anticonvulsant benzodiazepine within last month . Use psychotropic medication last week ( except state ) . Use steroid contraceptive within previous 4 month , include birth control pill , birth control patch , birth control ring , DepoProvera® . Subjects ask use abstinence barrier method ( condom ) form contraception study . Alcohol consumption great 7 drinks/week . Current pregnancy . Metallic implant .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>hormone</keyword>
	<keyword>menses</keyword>
	<keyword>PMS</keyword>
	<keyword>PMDD</keyword>
</DOC>